{"id":744971,"date":"2014-06-05T16:00:00","date_gmt":"2014-06-05T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/"},"modified":"2023-03-22T00:04:54","modified_gmt":"2023-03-22T04:04:54","slug":"first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/","title":{"rendered":"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir)"},"content":{"rendered":"<p class=\"bwalignc\">       ONCEMRK Study Globally Enrolling Treatment-Na\u00efve Adults with HIV-1     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the first patient has been enrolled in the<br \/>\n      company\u2019s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a<br \/>\n      once-daily investigational formulation of ISENTRESS<sup>\u00ae<\/sup><br \/>\n      (raltegravir), known as reformulated raltegravir, as part of combination<br \/>\n      HIV therapy for treatment-na\u00efve HIV-1-infected adults. ISENTRESS<br \/>\n      film-coated tablets are currently administered twice daily in accordance<br \/>\n      with the approved Prescribing Information.\n    <\/p>\n<p>\n      \u201cISENTRESS has been a significant component of first-line HIV-1<br \/>\n      treatment for more than six years, as a twice-daily component of<br \/>\n      antiretroviral therapy,\u201d said J\u00fcrgen Rockstroh, M.D., University of<br \/>\n      Bonn, Bonn-Venusberg, Germany, a clinical investigator on this study.<br \/>\n      \u201cWe look forward to advancing our understanding of this new formulation<br \/>\n      of once-daily raltegravir with this new trial.\u201d\n    <\/p>\n<p>\n      ISENTRESS is an integrase inhibitor indicated in combination with other<br \/>\n      antiretroviral (ARV) agents for the treatment of HIV-1 infection in<br \/>\n      patients four weeks of age and older. The use of other active agents<br \/>\n      with ISENTRESS is associated with a greater likelihood of treatment<br \/>\n      response. Severe, potentially life-threatening and fatal skin reactions<br \/>\n      have been reported with ISENTRESS. Additionally, during the initial<br \/>\n      phase of combination ARV treatment, immune reconstitution syndrome may<br \/>\n      occur. (See Important Selected Safety Information below).\n    <\/p>\n<p>\n      The ONCEMRK trial is a multicenter, double-blind, randomized,<br \/>\n      active-controlled study evaluating the safety, efficacy, tolerability<br \/>\n      and pharmacokinetics of reformulated raltegravir 1200 mg (dosed as two<br \/>\n      600 mg tablets) once daily, compared with ISENTRESS 400 mg twice daily,<br \/>\n      both in combination with once-daily tenofovir\/emtricitabine over 96<br \/>\n      weeks. The primary endpoint of the non-inferiority study is the<br \/>\n      proportion of patients achieving viral suppression (&lt;40 copies\/mL) at<br \/>\n      Week 48, which the company estimates will occur in the first half of<br \/>\n      2016. Each patient in the study will receive treatment for approximately<br \/>\n      96 weeks. To learn more about the ONCEMRK trial, contact Merck at<br \/>\n      1-888-577-8839 or visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinical-trials&amp;index=1&amp;md5=9159cf07f449f761cd021a6a8eab5b72\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinical-trials<\/a>.<br \/>\n      Additional details can also be found online at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02131233&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02131233&amp;index=2&amp;md5=96693bb6fec2dbaa59252c637632bd82\" rel=\"nofollow\">www.clinicaltrials.gov\/ct2\/show\/NCT02131233<\/a>.\n    <\/p>\n<p>\n      \u201cWe remain dedicated to investigating new applications for ISENTRESS and<br \/>\n      to further expanding our knowledge of this HIV-1 treatment,\u201d said Peter<br \/>\n      Sklar, M.D., M.P.H., director, Clinical Research, Merck Research<br \/>\n      Laboratories. \u201cMerck is proud to mark this notable milestone in the<br \/>\n      development of once-daily raltegravir and we look forward to continued<br \/>\n      patient enrollment worldwide over the coming months.\u201d\n    <\/p>\n<p>\n      More than 160 centers in more than 25 countries are expected to<br \/>\n      participate in the ONCEMRK trial in the coming months. Merck is planning<br \/>\n      for the program to include approximately 750 patients worldwide.\n    <\/p>\n<p>\n      <b>Investigations of Raltegravir Once Daily<\/b>\n    <\/p>\n<p>\n      Reformulated raltegravir is a novel non-poloxamer based formulation.<br \/>\n      Based on the results of several Phase 1 studies, reformulated<br \/>\n      raltegravir has shown the potential to be investigated further for once<br \/>\n      daily use.\n    <\/p>\n<p>\n      Data from the previous Phase 3 trial of raltegravir once daily, QDMRK,<br \/>\n      have contributed to the understanding of raltegravir pharmacokinetics<br \/>\n      and pharmacodynamics. QDMRK evaluated the long-term safety, tolerability<br \/>\n      and efficacy of a once-daily 800 mg ISENTRESS dose in a combination<br \/>\n      regimen compared with a twice-daily 400 mg ISENTRESS dose in<br \/>\n      combination. The once-daily arm of QDMRK studied the ISENTRESS poloxamer<br \/>\n      formulation given as two 400 mg tablets simultaneously. Results showed<br \/>\n      the primary endpoint of non-inferiority was not met, with 83 percent of<br \/>\n      treatment-na\u00efve adult HIV-1 infected patients achieving viral<br \/>\n      suppression (&lt;50 copies\/mL at Week 48) with the dosing regimen of 800 mg<br \/>\n      raltegravir once daily, compared with 89 percent of patients treated<br \/>\n      with ISENTRESS 400 mg twice daily. The safety and tolerability profiles<br \/>\n      of the two regimens were generally similar in the study and similar to<br \/>\n      the Prescribing Information for ISENTRESS.\n    <\/p>\n<p>\n      <b>Important Selected Safety Information<\/b>\n    <\/p>\n<p>\n      ISENTRESS does not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      Severe, potentially life-threatening and fatal skin reactions have been<br \/>\n      reported. This includes cases of Stevens-Johnson syndrome,<br \/>\n      hypersensitivity reaction and toxic epidermal necrolysis. Immediately<br \/>\n      discontinue treatment with ISENTRESS and other suspect agents if severe<br \/>\n      hypersensitivity, severe rash, or rash with systemic symptoms or liver<br \/>\n      aminotransferase elevations develop and monitor clinical status,<br \/>\n      including liver aminotransferases closely.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.\n    <\/p>\n<p>\n      ISENTRESS chewable tablets contain phenylalanine, a component of<br \/>\n      aspartame, which may be harmful to patients with phenylketonuria.\n    <\/p>\n<p>\n      Co-administration of ISENTRESS with drugs that are strong inducers of<br \/>\n      uridine diphosphate glucuronosyltransferase (UGT1A1) may result in<br \/>\n      reduced plasma concentrations of raltegravir. Co-administration of<br \/>\n      ISENTRESS with drugs that inhibit UGT1A1 may increase plasma levels of<br \/>\n      raltegravir. Co-administration of ISENTRESS and other drugs may alter<br \/>\n      the plasma concentration of raltegravir. The potential for drug-drug<br \/>\n      interactions (DDIs) must be considered prior to and during therapy.<br \/>\n      Co-administration or staggered administration of aluminum and\/or<br \/>\n      magnesium hydroxide-containing antacids and ISENTRESS is not<br \/>\n      recommended. Rifampin, a strong inducer of UGT1A1, reduces plasma<br \/>\n      concentrations of ISENTRESS. Therefore, the dose of ISENTRESS for adults<br \/>\n      should be increased to 800 mg twice daily during coadministration with<br \/>\n      rifampin. There are no data to guide co-administration of ISENTRESS with<br \/>\n      rifampin in patients below 18 years of age.\n    <\/p>\n<p>\n      The most commonly reported (\u22652%) drug-related clinical adverse reactions<br \/>\n      of moderate to severe intensity in treatment-na\u00efve adult patients<br \/>\n      receiving ISENTRESS compared with efavirenz were insomnia (4% vs 4%),<br \/>\n      headache (4% vs 5%), nausea (3% vs 4 %), fatigue (2% vs 3%), and<br \/>\n      dizziness (2% vs 6%), respectively. In treatment-experienced adult<br \/>\n      patients receiving ISENTRESS, the most commonly reported (\u22652%)<br \/>\n      drug-related clinical adverse reactions of moderate to severe intensity<br \/>\n      and at a higher incidence compared with placebo was headache (2% vs<br \/>\n      &lt;1%). In both studies, intensities were defined as: Moderate (discomfort<br \/>\n      enough to cause interference with usual activity); or Severe<br \/>\n      (incapacitating with inability to work or do usual activity). In<br \/>\n      treatment-experienced pediatric patients 4 weeks through 18 years of age<br \/>\n      receiving ISENTRESS, the frequency, type and severity of drug- related<br \/>\n      adverse reactions were comparable to those observed in adults.\n    <\/p>\n<p>\n      Grade 2 to 4 creatine kinase laboratory abnormalities were observed in<br \/>\n      patients treated with ISENTRESS. Myopathy and rhabdomyolysis have been<br \/>\n      reported. Use with caution in patients at increased risk of myopathy or<br \/>\n      rhabdomyolysis, such as patients receiving concomitant medications known<br \/>\n      to cause these conditions and patients with a history of rhabdomyolysis,<br \/>\n      myopathy or increased serum creatine kinase.\n    <\/p>\n<p>\n      ISENTRESS should be used during pregnancy only if the potential benefit<br \/>\n      justifies the potential risk to the fetus. There are no adequate and<br \/>\n      well-controlled studies in pregnant women. In addition, there have been<br \/>\n      no pharmacokinetic studies conducted in pregnant women. To monitor<br \/>\n      maternal-fetal outcomes of pregnant patients exposed to ISENTRESS, an<br \/>\n      Antiretroviral Pregnancy Registry has been established. Physicians are<br \/>\n      encouraged to register patients by calling 1-800-258-4263.\n    <\/p>\n<p>\n      <b>About ISENTRESS<\/b>\n    <\/p>\n<p>\n      ISENTRESS is Merck&#8217;s integrase inhibitor for the treatment of HIV-1<br \/>\n      infection in adult and pediatric patients ages four weeks and older and<br \/>\n      weighing at least 3 kg as part of combination HIV therapy. ISENTRESS<br \/>\n      works by inhibiting the insertion of HIV-1 DNA into human DNA by the<br \/>\n      integrase enzyme and has demonstrated rapid antiviral activity.<sup> <\/sup>Inhibiting<br \/>\n      integrase from performing this essential function limits the ability of<br \/>\n      the virus to replicate and infect new cells.<b> <\/b>ISENTRESS is now<br \/>\n      approved as part of combination therapy in more than 76 countries for<br \/>\n      use in treatment-na\u00efve adult patients with HIV-1 and in more than 114<br \/>\n      countries for use in treatment-experienced adult patients with HIV-1.<br \/>\n      ISENTRESS, in combination therapy, for use in children and adolescents<br \/>\n      with HIV-1 ages two years and older has also been approved for use in 35<br \/>\n      countries, and ISENTRESS oral suspension for infants at least four weeks<br \/>\n      of age is approved for use in the U.S. Merck is continuing to move<br \/>\n      forward with filings of ISENTRESS for oral suspension in additional<br \/>\n      countries around the world.\n    <\/p>\n<p>\n      To assist patients taking ISENTRESS, Merck offers the SUPPORT\u2122 program,<br \/>\n      which provides personal support and patient advocacy regarding<br \/>\n      individual reimbursement issues. For more information about the SUPPORT\u2122<br \/>\n      program, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckhelps.com&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=www.merckhelps.com&amp;index=3&amp;md5=f16e23940cd22b32f2ba22f5b9d07ef8\" rel=\"nofollow\">www.merckhelps.com<\/a><br \/>\n      or call 1-800-850-3430.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=4c22ce16a7be57fb5d2fc04f7c5aa97d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=ce55e26c5ec46ff7e248464ee44fea5a\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=984e3efb40b6007a16db4df13de44720\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=292e7e6241b5495468c3d467f46b66c4\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=09ce5a094dbc24e216d586c6a4e67629\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ISENTRESS (raltegravir) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;index=9&amp;md5=d5b48d880259d1412491f38b73677c8e\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf<\/b><\/a><b><br \/>\n      and Patient Information for ISENTRESS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;esheet=50880349&amp;newsitemid=20140605006239&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;index=10&amp;md5=756e6c9ec9c12b559c956826f27fcd79\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>ISENTRESS<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of<br \/>\n      Merck &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Caroline Lappetito, 267-305-7639<br \/>Sarra        Herzog, 908-423-6154<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ONCEMRK Study Globally Enrolling Treatment-Na\u00efve Adults with HIV-1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company\u2019s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS\u00ae (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-na\u00efve HIV-1-infected adults. ISENTRESS film-coated tablets are currently administered twice daily in accordance with the approved Prescribing Information. \u201cISENTRESS has been a significant component of first-line HIV-1 treatment for more than six years, as a twice-daily component of antiretroviral therapy,\u201d said J\u00fcrgen Rockstroh, M.D., University of Bonn, Bonn-Venusberg, Germany, a clinical investigator on this study. \u201cWe look forward to advancing our understanding of this new formulation of once-daily raltegravir with this new trial.\u201d ISENTRESS is an integrase<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-744971","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"ONCEMRK Study Globally Enrolling Treatment-Na\u00efve Adults with HIV-1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company\u2019s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS\u00ae (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-na\u00efve HIV-1-infected adults. ISENTRESS film-coated tablets are currently administered twice daily in accordance with the approved Prescribing Information. \u201cISENTRESS has been a significant component of first-line HIV-1 treatment for more than six years, as a twice-daily component of antiretroviral therapy,\u201d said J\u00fcrgen Rockstroh, M.D., University of Bonn, Bonn-Venusberg, Germany, a clinical investigator on this study. \u201cWe look forward to advancing our understanding of this new formulation of once-daily raltegravir with this new trial.\u201d ISENTRESS is an integrase\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/\",\"name\":\"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2014-06-05T16:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/","og_locale":"en_US","og_type":"article","og_title":"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com","og_description":"ONCEMRK Study Globally Enrolling Treatment-Na\u00efve Adults with HIV-1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company\u2019s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS\u00ae (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-na\u00efve HIV-1-infected adults. ISENTRESS film-coated tablets are currently administered twice daily in accordance with the approved Prescribing Information. \u201cISENTRESS has been a significant component of first-line HIV-1 treatment for more than six years, as a twice-daily component of antiretroviral therapy,\u201d said J\u00fcrgen Rockstroh, M.D., University of Bonn, Bonn-Venusberg, Germany, a clinical investigator on this study. \u201cWe look forward to advancing our understanding of this new formulation of once-daily raltegravir with this new trial.\u201d ISENTRESS is an integrase","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:54+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/","name":"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","datePublished":"2014-06-05T16:00:00+00:00","dateModified":"2023-03-22T04:04:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140605006239r1&amp;sid=hq1sf1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-patient-enrolled-in-new-phase-3-trial-program-investigating-a-once-daily-dosing-regimen-of-isentress-raltegravir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS\u00ae (raltegravir)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"021470d3-f525-4993-9f67-f0483ed6a5ee","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/First-Patient-Enrolled-in-New-Phase-3-Trial-Program-Investigating-a-Once-Daily-Dosing-Regimen-of-ISENTRESS-raltegravir-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744971\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744971"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}